8 terminated. 8 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 4 | Terminated 4 |
Follow Electrocardiogram: new trials by email Literature Review of Electrocardiogram trials Research Report on Electrocardiogram
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Sacituzumab Govitecan, EKG, Brain MRI - Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2025-06-09 | 2026-01-21 |
| Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma Olaparib, ECG, CT CAP - Pancreatic Acinar Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2023-12-14 | 2026-08-14 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors Olaparib, Durvalumab, EKG - EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2021-07-07 | 2026-09-22 |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients Cyclophosphamide, Fludarabine, Aldesleukin - Gastrointestinal Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-05-16 | 2026-05-19 |
| Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers Nivolumab, EKG, MRI Brain and/or spine - Medulloblastoma, Ependymoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 136 | 2017-07-13 | 2026-10-27 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 45 | 2016-05-09 | 2026-08-13 |
Myelodysplastic Syndromes (2) · Brain Neoplasms (1) · Carcinoma, Transitional Cell (1) · Choroid Plexus Neoplasms (1) · Colonic Neoplasms (1) · Cytopenia (1) · Ependymoma (1) · Gastrointestinal Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Medulloblastoma (1) · Meningioma (1) · Pancreatic Neoplasms (1) · Pinealoma (1) · Prostatic Neoplasms (1)
National Cancer Institute (NCI) (8)
United States (8)
Najla El Jurdi, M.D. (2) · Anish Thomas, M.D. (1) · Chen Zhao, M.D. (1) · James C Yang, M.D. (1) · James Gulley, M.D. (1) · Kevin C Conlon, M.D. (1) · Kevin Camphausen, M.D. (1)